These players have had their ups and downs -- but the future looks bright. Though the S&P 500 dipped earlier this month, it's important to keep in mind that we're still in a very positive market environment. The bull market is going strong, with the benchmark rising 17% so far this year. And since bull phases generally last longer than bear ones, it's possible that the good times will keep on rolling. How can you benefit? By scooping up a few players that haven't yet picked up momentum but have the potentia ...

Key Takeaways The S&P 500 added 0.8% on Thursday, Sept. 12, 2024, extending its winning streak to four days as the latest PPI data showed a softening in wholesale inflation. Warner Bros. Discovery shares surged after entertainment giant renewed its distribution deal with Charter Communications. Kroger's stock rose on earnings news. Moderna said it will cut back on research and development spending, and shares of the vaccine maker plunged. Major U.S. equities indexes headed higher after the latest Producer P ...

Shares of Moderna Inc (NASDAQ:MRNA) are plummeting today, after the biotech giant announced it was slashing its research budget by about 20%. The company also teased the launch of 10 new products before then. On the short sell restricted (SSR) list amid the volatility, MRNA was last seen down 17.8% at $65.38, hitting its lowest levels since early November. The stock has continued to move lower since its 21.1% post-earnings drop on August 1, and is currently down 35.4% year to date. Options traders are chimi ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in major cities such as London, New York, and Sydney [2] Group 2 - The company utilizes technology to enhance workflows and has adopted automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 12, 2024 /PRNews ...

Key Takeaways Moderna shares fell Thursday morning after the COVID vaccine maker announced plans to trim its research and development pipeline to cut costs. The company said it will focus on getting FDA approval for 10 products to treat RSV and cancer, along with a combination COVID and flu vaccine. Moderna said it expects the moves to lower expenses by $1.1 billion by 2027. Moderna (MRNA) shares tumbled in pre-market trading Thursday as the company said it plans to cut costs and suspend or end development ...

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product approvals through 2027. But Moderna said it will also pause work on some products in its pipeline and scrap others, as it aims to "pace ourselves" in new research and development spending. The company aims to trim R&D spending to a range of $3.6 billion to $3.8 ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=101868&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced th ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...